Suprofen kinetics in healthy male volunteers after intramuscular injection of increasing dosages.
Kinetics of alpha-methyl-4-(2-thienyl-carbonyl)-phenylacetic acid (suprofen, Suprol) a non-narcotic antiphlogistic analgesic, were studied in two clinical experiments. In a bioavailability study (study A) suprofen, given as intramuscular injection was absorbed more rapidly (mean peak plasma time 20.0 min) than from the capsule formulation (mean peak plasma time 57.5 min). With respect to the amount systemically absorbed, measured as area under the plasma concentration-time curve, both dosage forms were equivalent. Individual plasma concentration profiles (study B) were described by a 2-compartmental model with a mean first order absorption rate of 0.095 min-1, a rapid mean disposition rate alpha of 0.025 min-1 and an apparent terminal plasma elimination rate beta of 0.004 min-1. There was dose-independent kinetics and a linear correlation between peak plasma concentration versus dose and area under the curve (AUC) versus dose after intramuscular injection of suprofen up to 200 mg, leading to dose proportional bioavailability data.
D000328:Adult; D001682:Biological Availability; D006801:Humans; D007273:Injections, Intramuscular; D007700:Kinetics; D008297:Male; D008954:Models, Biological; D010666:Phenylpropionates / Q000378:metabolism*; D013496:Suprofen / Q000008:administration & dosage / Q000378:metabolism*
D010666:Phenylpropionates; D013496:Suprofen